Innovation Pharma (Formerly known as Cellceutix)

254 articles with Innovation Pharma (Formerly known as Cellceutix)

• Innovation Pharmaceuticals Announces NIH/NIAID-Affiliated Researchers to Evaluate Brilacidin's Treatment Potential Against Monkeypox

  8/5/2022

  Innovation Pharmaceuticals, a clinical stage biopharmaceutical company, announced that Brilacidin, the Company's defensin-mimetic drug candidate exhibiting broad-spectrum antiviral properties, is to be evaluated for its treatment potential against the monkeypox virus.

• Provider and Payer Analysis Supports Potential Commercialization of Innovation Pharmaceutical's Brilacidin as a Novel Oral Mucositis Drug Candidate

  7/22/2022

  Provider and Payer Analysis Supports Potential Commercialization of Innovation Pharmaceutical's Brilacidin as a Novel Oral Mucositis Drug Candidate.

• Innovation Pharmaceuticals Announces New Antiviral Research on Brilacidin in Bunyaviruses and Alphaviruses to be Presented at the 2022 Military Health System Research Symposium

  6/28/2022

  Innovation Pharmaceuticals today announced new antiviral research on Brilacidin in vitro antiviral activity in bunyaviruses and alphaviruses has been accepted for a Poster Presentation at the 2022 Military Health System Research Symposium.

• Innovation Pharmaceuticals Reports Brilacidin Inhibits Omicron, Delta, Gamma and Alpha SARS-CoV-2 Variants Based on In Vitro Testing by NIH/NIAID-Sponsored and Rutgers University Researchers

  6/23/2022

  Innovation Pharmaceuticals today reported that Brilacidin, the Company's defensin-mimetic drug candidate exhibiting broad-spectrum antiviral activity, inhibited the Omicron (B.1.1.529) and Delta (B.1.617.2) variants of SARS-CoV-2 based on in vitro testing conducted in collaboration with National Institutes of Health (NIH).

• Innovation Pharmaceuticals Acquires Stake in Squalus Medical, Seeks to Reshape Cancer and Epilepsy Treatments Through a New Image Guided Laser-Based Ablation Technology

  6/15/2022

  Innovation Pharmaceuticals announced that the Company has acquired a minority stake in Israel-based Squalus Medical, the inventor and developer of the StingRay Laser System, a novel laser-based thermal ablation technology designed for treatment of previously inoperable cases of epilepsy and for improvement of outcomes and enablement of new treatment options for oncology procedures, including those treating brain, prostate, liver, breast and lung cancers.

• Innovation Pharmaceuticals Announces Publication of Peer-Review Article in the Journal of Medical Virology on Anti-Coronavirus Properties of Brilacidin

  3/15/2022

  Innovation Pharmaceuticals, a clinical stage biopharmaceutical company, announced publication of a peer-review scientific article in the Journal of Medical Virology on the anti-coronavirus properties of Brilacidin.

• 

  Clinical Catch-Up: Pfizer's Paxlovid, Immunome Set and Gilead's Trodelvy

  3/14/2022

  Across a range of indications, COVID-19-related and non-COVID-19-related, there was plenty of clinical trial news last week.

• Innovation Pharmaceuticals Reports Additional Findings Based on Review of Brilacidin Phase 2 COVID-19 Trial Results and Compassionate Use Cases

  3/7/2022

  Innovation Pharmaceuticals today reported findings from data review of the Company's Brilacidin Phase 2 COVID-19 study and compassionate use of Brilacidin in critically-ill COVID-19 patients.

• Innovation Pharmaceuticals Analyzing Full Dataset for Its Brilacidin COVID-19 Clinical Trial; Company Evaluating New Pipeline Opportunities for 2022

  12/7/2021

  Innovation Pharmaceuticals today provides shareholders with perspectives on the Company's go-forward strategy heading into 2022.

• Innovation Pharmaceuticals Provides Brilacidin Program Update

  11/18/2021

  Innovation Pharmaceuticals, a clinical stage biopharmaceutical company, provided an update on clinical development plans for Brilacidin, the Company's defensin-mimetic drug candidate being evaluated in clinical testing for multiple indications.

• Innovation Pharmaceuticals Conducting Full Data Analysis of Phase 2 Brilacidin COVID-19 Trial Results to Support Brilacidin's Potential Inclusion in Government-Sponsored COVID-19 Trials

  11/12/2021

  Innovation Pharmaceuticals today announced the Company is conducting full data analysis of the Phase 2 Brilacidin COVID-19 clinical trial results to support Brilacidin

• Innovation Pharmaceuticals Announces Topline Results from Phase 2 Clinical Trial of Brilacidin for COVID-19

  11/11/2021

  Innovation Pharmaceuticals, a clinical stage biopharmaceutical company, reported topline results from the Company's Phase 2 clinical trial of Brilacidin in hospitalized patients with moderate-to-severe COVID-19.

• Database Lock Completed for Innovation Pharmaceuticals' Phase 2 Clinical Trial of Brilacidin for COVID-19

  11/3/2021

  Innovation Pharmaceuticals today announced that the Company has received confirmation that hard lock of the database was completed for its Phase 2 clinical trial of Brilacidin for treatment of moderate-to-severe COVID-19 in hospitalized patients (see NCT04784897 ).

• Innovation Pharmaceuticals Provides Update on COVID-19 Clinical Trial, Compassionate Use Requests and Research into Brilacidin's Broad-Spectrum Antiviral Properties

  9/23/2021

  Innovation Pharmaceuticals today provided an update on the status of its randomized, double-blind, placebo-controlled Phase 2 clinical trial of Brilacidin for the treatment of moderate-to-severe COVID-19 in hospitalized patients

• Innovation Pharmaceuticals Provides Update on Brilacidin Antiviral Research

  8/2/2021

  Innovation Pharmaceuticals, a clinical stage biopharmaceutical company, provided an update on ongoing antiviral research of Brilacidin, the Company’s defensin-mimetic drug candidate being developed for treatment of COVID-19 under FDA Fast Track designation, by different groups of scientists.

• Innovation Pharma Completes Enrollment in Phase 2 Clinical Trial for COVID-19

  6/3/2021

  Innovation Pharmaceuticals, a clinical stage biopharmaceutical company, announced that it has achieved full patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 clinical trial of Brilacidin for the treatment of moderate-to-severe COVID-19 in hospitalized patients.

• Innovation Pharma Surpasses 50 Percent Enrollment in Phase 2 Clinical Trial of Brilacidin for COVID-19

  4/28/2021

  Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announced that enrollment has surpassed 50 percent of the total targeted number of randomized trial participants (~n=120) in its double-blind, placebo-controlled Phase 2 clinical trial of Brilacidin for treatment of moderate-to-severe COVID-19

• Innovation Pharma Completes Interim Safety Data Review—DMC Approves Increased Dosing Frequency in Phase 2 Clinical Trial of Brilacidin in Hospitalized COVID-19 Patients

  4/5/2021

  Study drug dosing regimen to increase to 5 days (from 3 days) based on DMC recommendation Enrollment has reached 25 percent in the Company’s ~120-patient Phase 2 COVID-19 clinical trial

• 

  2021 Biopharma Update on the Novel Coronavirus: March 16

  3/16/2021

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for March 16, 2021.

• Innovation Pharma’s COVID-19 Drug Candidate Brilacidin Ranked in Top Three Percent of Compounds Predicted to Be Most Effective Against SARS-CoV-2

  3/10/2021

  Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to report today that a Machine Learning (Artificial Intelligence) model used to screen 1,482 compounds ranked Brilacidin in the top three percent of compounds predicted to be the most effective against SARS-CoV-2